This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q61651401
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована у квітні 2011 artículu científicu espublizáu n'abril de 2011 scientific article published on 01 April 2011 wetenschappelijk artikel im April 2011 veröffentlichter wissenschaftlicher Artikel article scientifique publié en 2011
p:P577
wds:Q61651401-FE96FAB3-E101-46BB-A918-DCA0BBC5BC8A
wdt:P577
2011-04-01T00:00:00Z
p:P2093
wds:Q61651401-87A581B4-0258-4370-A9A0-4FE6B978FF5C
wdt:P2093
Eric Van Remortel
rdfs:label
The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents
skos:prefLabel
The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents
schema:name
The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents
p:P50
wds:Q61651401-6BB7E27F-0F94-4E56-B3D0-5E2FB08FA985 wds:Q61651401-82D79B9A-EED7-4269-BAD8-DB6B88C3594B wds:Q61651401-9377939F-AE69-4E65-A1D1-A1FB36C6B2E4 wds:Q61651401-BEB4B82C-B70C-4AA4-A6C7-4FAEC3CA113D wds:Q61651401-BFAAFC5C-7BF0-4505-80E3-D5C0FCD2B6FE wds:Q61651401-C6941102-B947-4823-8B5D-4A120A658039 wds:Q61651401-CB10F941-CAE0-4FE9-9682-0874A953829A wds:Q61651401-D37BF7E5-DB2C-4667-9596-EF13749232DC wds:Q61651401-DD9A41B3-CEC7-408D-9987-ED3DA4073DEE wds:Q61651401-E4B5E539-A27D-4AA5-9BD7-E30987BEA786 wds:Q61651401-0FAB9286-DAD8-4A2A-93B9-F07258EE3984 wds:Q61651401-1C0E3A71-AC0B-4E26-B679-8AD3CC606DAF wds:Q61651401-2A2EE262-9068-4FAA-B67F-CE78A8AD8AFC wds:Q61651401-35D6F714-82BF-4B57-B67C-ECA95ADAF56B wds:Q61651401-3FA56075-5B3B-4A68-9E3D-4D8D0F0A5756 wds:Q61651401-4480199B-D7CB-4634-93CD-7BDC11AAED15 wds:Q61651401-4499FAA1-2348-4069-A41C-A63A5D08FA5C wds:Q61651401-4729FABD-DCE3-479A-A8D9-02BD3BFAEFAC wds:Q61651401-4F03A949-98A7-4FD7-8009-EE1DB28E13F2 wds:Q61651401-5CD87A74-7149-491A-8E02-F272A850AFDF wds:Q61651401-EEAA8FB3-75FB-411D-87E4-7784DAF87958 wds:Q61651401-F9C323D1-93DD-4405-AF2D-724C3187D44D
wdt:P50
wd:Q63253317 wd:Q63256285 wd:Q106623025 wd:Q88839481 wd:Q11813975 wd:Q114309768 wd:Q37830796 wd:Q114309769 wd:Q114309648 wd:Q99205030 wd:Q114304458 wd:Q61278410 wd:Q88614941 wd:Q114258202 wd:Q101056967 wd:Q114309716 wd:Q114309626 wd:Q114309625 wd:Q58796459 wd:Q114304439 wd:Q114309596 wd:Q54396667
p:P1476
wds:Q61651401-B254E694-76A1-42B3-BBF5-4E876ABAD380
wdt:P1476
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial
p:P304
wds:Q61651401-225B6C12-5BEF-4FD1-A194-742B28D1A404
wdt:P304
432-441
p:P31
wds:Q61651401-A3F2E425-65AC-44D3-830A-0C1C9FF1C11F
wdt:P31
wd:Q13442814
p:P921
wds:Q61651401-F63BB575-1D49-4AEF-867C-651A55F3965E
wdt:P921
wd:Q7317735
p:P698
wds:Q61651401-6965C385-5E92-4FD5-BAB2-CB88B59C875D
wdtn:P698
n9:21511223
wdt:P698
21511223
p:P1433
wds:Q61651401-38C5F26D-6B4E-4D79-A9A4-2CE5AC75D61B
wdt:P1433
wd:Q15816248
p:P433
wds:Q61651401-1B19BB01-114D-4F10-8106-27AB260BCC0B
p:P478
wds:Q61651401-83140CA8-3984-4F68-94BA-838CD5FC4FD6
wdt:P433
4
wdt:P478
4
p:P356
wds:Q61651401-B457982E-23C4-4987-A118-00A3E3C75210
wdtn:P356
n11:J.JCIN.2011.01.008
wdt:P356
10.1016/J.JCIN.2011.01.008